pharmaceutical

National Institute of Health partners with 11 Biopharma companies for Cancer Research

National Institute of Health partners with 11 Biopharma companies for Cancer Research

The National Institutes of Health and 11 biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT). This is a five-year-public-private research collaboration totaling $215 million as part of the Cancer Moons..

Pfizer Considers the Sales of its Consumer Healthcare Business

Pfizer Considers the Sales of its Consumer Healthcare Business

On Tuesday, Pfizer Inc. (NYSE: PFE), the pharmaceutical giant, said that it is considering the sale or spin-off of its consumer healthcare business, whose brands include lip balm Chapstick and painkiller Advil.The company’s consumer healthcare..

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigatio..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated Shares Jumped More than 100% After Positive Clinical Trial Data

Insmed Incorporated (NASDAQ: INSM) stock jumped about 113% on Tuesday, after the biopharmaceutical company announced top-line data from its Phase 3 CONVERT study.The company announced that the global CONVERT study met its primary endpoint of culture..

Novartis Immunocellular Therapy Approved by FDA

Novartis Immunocellular Therapy Approved by FDA

Novartis AG (NYSE: NVS) announced Wednesday that the US Food and Drug Administration (FDA) has approved Kymriah (TM)(tisagenlecleucel) suspension for intravenous infusion, the first chimeric antigen receptor T cell (CAR-T) therapy, for the treatment..